Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis
Authors:
Open Access
- 4 February 2025
- journal article
- review article
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 11 (3) , 251-263
Abstract
Aims: Transcatheter mitral valve replacement (TMVR) has become a feasible alternative to surgical mitral valve replacement (SMVR) in selected patients at high surgical risk. The risk of valve thrombosis following SMVR and TMVR, and the optimal antithrombotic therapy following these procedures, remains uncertain. We aimed to compare the incidence of bioprosthetic mitral valve thrombosis (bMVT) after SMVR and TMVR, and the incidence of bMVT between patients on different antithrombotic regimens. Methods and results: A literature search of Medline, Embase, and Cochrane Library was performed between January 2000 and August 2024. Random-effects models were used to derive pooled estimates of the incidence of bMVT in the absence of prior or active endocarditis and valve thrombosis. A total of 47 studies (6170 patients, total follow-up 9541.8 patient-years) were eligible for inclusion. The overall incidence of bMVT was 5.05 [95% confidence interval (CI) 3.18–8.01, I2 = 82%] per 100-patient-years. Subclinical bMVT was more common than clinically significant bMVT: incidence 19.11 vs. 7.91 per 100-patient-years, adjusted incidence rate ratio (aIRR) 4.62 (95% CI 1.39–15.36), P = 0.012. bMVT was numerically more common after TMVR than SMVR, but the comparison was not statistically significant: incidence 7.03 vs. 0.58 per 100-patient-years, aIRR 2.19 (95% CI 0.72–6.72), P = 0.170. Patients on vitamin-K antagonists (VKA) had a lower incidence of bMVT than patients on direct oral anticoagulants (DOAC; incidence 5.72 vs. 17.08, aIRR 0.31, 95% CI 0.13–0.73, P = 0.007). Conclusions: bMVT is not uncommon, with numerically higher incidence in transcatheter compared to surgical valves, but the comparison was not statistically significant. VKAs are associated with a lower incidence of bMVT compared to DOACs.Keywords
This publication has 40 references indexed in Scilit:
- Subclinical Leaflet Thrombosis and Anticoagulation After Transcatheter Aortic Valve ReplacementJAMA Cardiology, 2022
- Immobile Leaflets at Time of Bioprosthetic Valve Implantation: A Novel Risk Factor for Early Bioprosthetic FailureHeart, Lung and Circulation, 2022
- Bioprosthetic Aortic Valve Leaflet Thickening in the Evolut Low Risk Sub-StudyJACC, 2020
- Initial Feasibility Study of a New Transcatheter Mitral ProsthesisJACC, 2019
- Prosthetic Heart Valve ThrombosisJACC, 2016
- Methods to estimate the between‐study variance and its uncertainty in meta‐analysisResearch Synthesis Methods, 2015
- A basic introduction to fixed-effect and random-effects models for meta-analysisResearch Synthesis Methods, 2010
- A graphical method for exploring heterogeneity in meta‐analyses: application to a meta‐analysis of 65 trialsStatistics in Medicine, 2002
- Meta-analysis of Observational Studies in EpidemiologyA Proposal for ReportingJAMA, 2000
- High risk of thromboemboli early after bioprosthetic cardiac valve replacementJACC, 1995